4-氨基-N,N-二甲基苯磺酰胺 | 1709-59-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氨基-N,N-二甲基苯磺酰胺
• 中文别名: 4-氨基-N,N-二甲基苯
• 英文名称: 4-amino-N,N-dimethylbenzenesulphonamide
• 英文别名: 4-amino-N,N-dimethylbenzenesulfonamide；N,N-dimethyl-4-aminobenzenesulfonamide；4-amino-N,N-dimethylbenzene-1-sulfonamide；1-aminobenzene-4-sulphonic acid dimethylamide；p-Amino-N,N-dimethylbenzenesulfonamide
• CAS: 1709-59-7
• 化学式: C₈H₁₂N₂O₂S
• mdl: MFCD00031428
• 分子量: 200.261
• InChiKey: BABGMPQXLCJMSK-UHFFFAOYSA-N

物化性质

• 熔点：
  170-172°C
• 沸点：
  352.9±44.0 °C(Predicted)
• 密度：
  1.2581 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• TSCA：
  Yes
• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 危险类别：
  IRRITANT
• 安全说明：
  S26,S36/37/39
• WGK Germany：
  3
• 储存条件：
  2-8°C，避光干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N,N-Dimethyl 4-aminobenzenesulfonamide
Synonyms: N1-dimethylsulfanilamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H317: May cause an allergic skin reaction
P280: Wear protective gloves/protective clothing/eye protection/face protection

---

Section 3. Composition/information on ingredients.
Ingredient name: N,N-Dimethyl 4-aminobenzenesulfonamide
CAS number: 1709-59-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H12N2O2S
Molecular weight: 200.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氨基-N,N-二甲基苯磺酰胺 在 盐酸 、 碳酸氢钠 、 丙酮 作用下， 生成 4-{[(4-氨基苯基)磺酰基]氨基}-N,N-二甲基苯磺酰胺
  参考文献：
  名称：

  Itai; Yamamoto, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1938, vol. 58, p. 683,684, 686

  摘要：

  DOI：
• 作为产物：
  描述：

  对乙酰胺基苯磺酰氯 在 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 123.0h， 生成 4-氨基-N,N-二甲基苯磺酰胺
  参考文献：
  名称：

  基于喹诺酮支架的 DC-SIGN 类药物抑制剂

  摘要：

  DC-SIGN（树突状细胞特异性细胞间粘附分子-3-抓取非整联蛋白）是一种在免疫细胞上表达的模式识别受体，参与识别各种病原体（包括 HIV、埃博拉病毒和 SARS-CoV）上存在的碳水化合物特征-2。因此，开发阻断 DC-SIGN 碳水化合物结合位点的抑制剂可以产生一种有价值的工具来研究该受体在多种传染病中的作用。在此，我们使用 4-喹诺酮作为支架进行了基于片段的配体设计。我们合成了一个包含 61 种化合物的库，使用 STD 报告基因分析对 DC-SIGN 进行了筛选，并使用基于蛋白质的1 H– 15验证了这些数据NHSQC 核磁共振。基于构效关系数据，我们证明 2 位或 3 位的乙氧基羰基或二甲基氨基羰基有利于 DC-SIGN 结合活性，尤其是与 7 位或 8 位的氟、乙氧基羰基或二甲基氨基羰基组合。此外，我们证明这些喹诺酮类药物可以变构调节碳水化合物结合位点，这为这一具有挑战性的蛋白质靶标提供了另一种方法。

  DOI：

  10.1021/acsmedchemlett.2c00067

文献信息

• [EN] PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS<br/>[FR] PYRROLOTRIAZINES EN TANT QU'INHIBITEURS D'ALK ET DE JAK2
  申请人：CEPHALON INC

  公开号：WO2010071885A1

  公开（公告）日：2010-06-24

  The present invention provides a compound of formula (I) or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula (I) has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了一种式（I）的化合物或其盐形式，其中Q1、Q2、Q3和Q4如本文所定义。式（I）的化合物具有ALK和/或JAK2抑制活性，并可用于治疗增殖性疾病。
• One-Pot, Metal-Free Conversion of Anilines to Aryl Bromides and Iodides
  作者：Derek A. Leas、Yuxiang Dong、Jonathan L. Vennerstrom、Douglas E. Stack

  DOI：10.1021/acs.orglett.7b00771

  日期：2017.5.19

  A metal-free synthesis of aryl bromides and iodides from anilines via halogen abstraction from bromotrichloromethane and diiodomethane is described. This one-pot reaction affords aryl halides from the corresponding anilines in moderate to excellent yields without isolation of diazonium salts. The transformation has short reaction times, a simple workup, and insensitivity to moisture and air and avoids

  描述了通过从溴代三氯甲烷和二碘代甲烷中提取卤素从苯胺无金属合成芳基溴化物和碘化物。该一锅法反应以中等至优异的收率从相应的苯胺提供了卤代芳基卤化物，而没有分离出重氮盐。该转化反应时间短，后处理简单，对湿气和空气不敏感，并且避免了过多的卤化。DFT计算支持S RN 1机制。此方法代表了经典Sandmeyer反应的一种方便替代方法。
• Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors
  作者：Maria Letícia de Castro Barbosa、Lídia Moreira Lima、Roberta Tesch、Carlos Mauricio R. Sant'Anna、Frank Totzke、Michael H.G. Kubbutat、Christoph Schächtele、Stefan A. Laufer、Eliezer J. Barreiro

  DOI：10.1016/j.ejmech.2013.10.058

  日期：2014.1

  designed as EGFR and VEGFR-2 dual inhibitors were synthesized and evaluated for inhibitory effects. EGFR and VEGFR-2 are validated targets in cancer therapy and combined inhibition might be synergistic for both antitumor activity and resistance prevention. The biological data obtained proved the potential of 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors, highlighting

  合成了设计为EGFR和VEGFR-2双重抑制剂的新型2-氯-4-苯胺基喹唑啉并评估了其抑制作用。EGFR和VEGFR-2在癌症治疗中是经过验证的靶标，联合抑制可能在抗肿瘤活性和耐药性预防方面具有协同作用。获得的生物学数据证明了2-氯-4-苯胺基喹唑啉衍生物作为EGFR和VEGFR-2双重抑制剂的潜力，突出了化合物8o，其对VEGFR-2的效力大约高7倍，而效力则高11倍。在EGFR上与原型相比7。SAR和对接研究允许鉴定两种激酶的药效基团，并证明了氢键供体在对位的重要性苯胺部分与EGFR和VEGFR-2结合位点中保守的Glu和Asp氨基酸相互作用的位置。
• Synthesis, Plasmodium falciparum Inhibitory Activity, Cytotoxicity and Solubility of N2 ,N4 -Disubstituted Quinazoline-2,4-diamines.
  作者：Nattakarn Pobsuk、Praphasri Suphakun、Supa Hannongbua、Chanin Nantasenamat、Kiattawee Choowongkomon、M. Paul Gleeson

  DOI：10.2174/1573406415666181219100307

  日期：2019.8.26

  needed to produce new, more effective treatments. Quinazoline-2,4-diamines were identified as antiparasitic compounds over three decades ago and have remained of interest to date in industry and academia. OBJECTIVE An anti-malarial SAR evaluation of previously unreported N2 ,N4 -disubstituted quinazoline- 2,4-diamines have been undertaken in this study. We have synthesized and evaluated new derivatives against

  背景技术尽管制定了广泛的控制策略和治疗方案，但2015年仍报告了约2亿疟疾病例，导致约45万例死亡。由于抗病性问题，需要更多的药物开发努力以产生新的，更有效的治疗方法。喹唑啉-2,4-二胺在三十年前被鉴定为抗寄生虫化合物，迄今为止在工业界和学术界仍很受关注。目的在这项研究中对以前未报道的N2，N4-二取代的喹唑啉-2，4-二胺进行了抗疟SAR评估。我们已经合成和评估了抗恶性疟原虫的新衍生物，以试图更好地表征其生物学活性和整体物理特性。方法合成N2，N4-二取代的喹唑啉2 据报道，在放射性标记的次黄嘌呤掺入试验中，针对恶性疟原虫（Pf。）K1菌株具有4-二胺抑制剂活性。另外，使用基于MTT的在A549和Vero细胞系中测定了细胞毒性。使用基于摇瓶的方法在pH 7.4下评估关键化合物的水溶性。结果我们确定了化合物1和6p是恶性疟原虫的亚µM抑制剂，具有与氯喹同等的抗疟活性。化合物1和6m是恶性
• Pyrazolo [1,5-A] pyrimidine adenosine A2a receptor antagonists
  申请人：Clasby C. Martin

  公开号：US20060135526A1

  公开（公告）日：2006-06-22

  Compounds having the structural formula I are disclosed, wherein A is alkylene, or optionally substituted arylene, cycloalkylene or heteroaryldiyl; X is —C(O)— or —S(O) 2 —; R 1 is alkyl or cycloalkyl; R 2 is hydrogen, halo or —CN; R 3 is hydrogen or alkyl; R 4 is hydrogen, alkyl, alkoxy, hydroxyalkyl, aminoalkyl-, cycloalkyl, heterocycloalkyl, heterocycloalkyl substituted by alkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl; or R 3 and R 4 , form an optionally substituted 5-7 membered ring, said ring optionally comprising an additional heteroatom ring member; R 7 is alkyl, optionally substituted phenyl, optionally substituted heteroaryl, cycloalkyl, halo, morpholinyl, optionally substituted piperazinyl, or optionally substituted azacycloalkyl. Also disclosed is the use of the compounds in the treatment of Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, pharmaceutical compositions comprising them and kits comprising the components of the combinations.

  揭示了具有结构式I的化合物，其中A是烷基，或者可选择地取代的芳基，环烷基或杂芳基二基；X是—C(O)—或—S(O)2—；R1是烷基或环烷基；R2是氢，卤素或—CN；R3是氢或烷基；R4是氢，烷基，烷氧基，羟基烷基，氨基烷基，环烷基，杂环烷基，被烷基取代的杂环烷基，可选择地取代的芳基烷基或可选择地取代的杂芳基烷基；或者R3和R4形成一个可选择地取代的5-7成员环，所述环可选择地包含一个额外的杂原子环成员；R7是烷基，可选择地取代的苯基，可选择地取代的杂芳基，环烷基，卤素，吗啉基，可选择地取代的哌嗪基，或可选择地取代的氮杂环烷基。还揭示了这些化合物在帕金森病治疗中的用途，单独或与其他治疗帕金森病的药剂组合使用，包含它们的药物组合物和包含组合物组分的工具包。